Study to Assess Safety and Tolerability of Multiple Doses of EO2002

ConditionsCorneal Edema Corneal Endothelial Dystrophy Endothelial Dysfunction Fuchs Dystrophy Fuchs' Endothelial Dystrophy Bullous Keratopathy Pseudophakic Bullous Keratopathy Corneal Edema Pseudophakic

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorAsociación para Evitar la Ceguera en México

About this trial

The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.

Eligibility criteria

Qualifiers

Age ≥ 18 years.

Subject is phakic or pseudophakic with a posterior chamber intraocular lens (lens in the bag or sulcus).

Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs' corneal dystrophy or pseudophakic bullous keratopathy.

Disqualifiers

Other corneal disease

Anterior chamber intraocular lens

Sutured or scleral-fixated intraocular lens.

Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.

Trial design

Treatments tested in this trial

EO2002
Ripasudil

Treatment groups

12 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Asociación para Evitar la Ceguera en México

Lead sponsor

Emmecell

Collaborator

Source ClinicalTrials.gov